MAPK3 and cancer: The ERK1/2-RSK1/2-EphA2-GPRC5A signaling axis induced by cisplatin and carboplatin chemotherapy in serous ovarian carcinoma cell lines is closely correlated with acquired chemoresistance in cancer cells62.